A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects

NCT04488705 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: ETD002 - single dose
DRUG: Placebo - single dose
DRUG: ETD002 - 7 day repeat dose
DRUG: Placebo - 7 day repeat dose
DRUG: ETD002 - 14 day repeat dose
DRUG: Placebo - 14 day repeat dose
DRUG: Salbutamol

Sponsor

Enterprise Therapeutics Ltd